Quantitative in vivo cell-surface receptor imaging in oncology: kinetic modeling and paired-agent principles from nuclear medicine and optical imaging

The development of methods to accurately quantify cell-surface receptors in living tissues would have a seminal impact in oncology. For example, accurate measures of receptor density in vivo could enhance early detection or surgical resection of tumors via protein-based contrast, allowing removal of cancer with high phenotype specificity. Alternatively, accurate receptor expression estimation could be used as a biomarker to guide patient-specific clinical oncology targeting of the same molecular pathway. Unfortunately, conventional molecular contrast-based imaging approaches are not well adapted to accurately estimating the nanomolar-level cell-surface receptor concentrations in tumors, as most images are dominated by nonspecific sources of contrast such as high vascular permeability and lymphatic inhibition. This article reviews approaches for overcoming these limitations based upon tracer kinetic modeling and the use of emerging protocols to estimate binding potential and the related receptor concentration. Methods such as using single time point imaging or a reference-tissue approach tend to have low accuracy in tumors, whereas paired-agent methods or advanced kinetic analyses are more promising to eliminate the dominance of interstitial space in the signals. Nuclear medicine and optical molecular imaging are the primary modalities used, as they have the nanomolar level sensitivity needed to quantify cell-surface receptor concentrations present in tissue, although each likely has a different clinical niche.

[1]  F. Duran-Reynals Studies on the Localization of Dyes and Foreign Proteins in Normal and Malignant Tissues , 1939 .

[2]  D. Pressman,et al.  The use of paired labeling in the determination of tumor-localizing antibodies. , 1957, Cancer research.

[3]  D. Pressman,et al.  p-Iodobenzoyl groups as a paired label for in vivo protein distribution studies; specific localization of anti-tissue antibodies. , 1958, The International journal of applied radiation and isotopes.

[4]  A. Shaw,et al.  Chemical Differences between Antibody Fragments as shown by Paired Label Studies , 1962, Nature.

[5]  D. Pressman,et al.  Application of the paired label radioantibody technique to tissue sections and cell smears. , 1967, Journal of immunology.

[6]  AN APPROACH TO THE QUANTITATION OF IMMUNOGENIC ANTIGEN , 1968, The Journal of experimental medicine.

[7]  P. Nowell,et al.  QUANTITATIVE STUDIES ON THE MIXED LYMPHOCYTE INTERACTION IN RATS , 1968, The Journal of experimental medicine.

[8]  F. Dixon,et al.  Characterization of human anti-glomerular basement membrane antibodies eluted from glomerulonephritic kidneys. , 1970, The Journal of clinical investigation.

[9]  C. Wilson,et al.  Glomerular basement membrane--reactive antibody in anti-lymphocyte globulin. , 1971, The Journal of clinical investigation.

[10]  C. Wilson,et al.  Quantitation of acute and chronic serum sickness in the rabbit. , 1971, The Journal of experimental medicine.

[11]  C. Boone,et al.  Testing by the "paired-label" antibody binding technique for feline leukemia virus-induced cell surface antigens (FeLV-CSA) on the surface of human rhabdomyosarcoma cells releasing RD-114 virus. , 1973, Virology.

[12]  Surface Antigens on Cat Leukemic Cells Induced by Feline Leukemia Virus: Area Density and Antibody-Binding Affinity , 1973, Journal of virology.

[13]  J. Cerottini,et al.  In vivo localisation of radiolabelled antibodies to carcinoembryonic antigen in human colon carcinoma grafted into nude mice , 1974, Nature.

[14]  D. F. Preston,et al.  Photoscan localization of GW-39 tumors in hamsters using radiolabeled anticarcinoembryonic antigen immunoglobulin G. , 1974, Cancer research.

[15]  [Neoantigens on cells transformed by SV40. IV. - A quantitative study of antigenic sites in a cell line (TSV5C12) (author's transl)]. , 1975, Annales d'immunologie.

[16]  I. Fidler,et al.  Tumor heterogeneity and the biology of cancer invasion and metastasis. , 1978, Cancer research.

[17]  Marcus E. Raichle,et al.  Measurement of regional cerebral blood volume by emission tomography , 1978, Annals of neurology.

[18]  J R van Nagell,et al.  Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. , 1978, The New England journal of medicine.

[19]  [Use of radio-labelled monoclonal antibodies for the scintigraphic detection of human colorectal cancers]. , 1983, Bulletin du cancer.

[20]  C S Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[21]  M. Mintun,et al.  Brain blood flow measured with intravenous H2(15)O. II. Implementation and validation. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  F. Buchegger,et al.  Radiolabeled fragments of monoclonal antibodies against carcinoembryonic antigen for localization of human colon carcinoma grafted into nude mice , 1983, The Journal of experimental medicine.

[23]  R. Coleman,et al.  Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: paired-label and imaging analysis. , 1984, Anticancer research.

[24]  M. Mintun,et al.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.

[25]  C. Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. Generalizations , 1985, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[26]  R. McLendon,et al.  Production and characterization of two human glioma xenograft-localizing monoclonal antibodies. , 1986, Cancer research.

[27]  M. Zalutsky,et al.  A method for the radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine. , 1987, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[28]  C. Patlak,et al.  Regional localization of a glioma-associated antigen defined by monoclonal antibody 81C6 in vivo: kinetics and implications for diagnosis and therapy. , 1987, Cancer research.

[29]  N. de Tribolet,et al.  In vivo localisation of radiolabelled monoclonal antibody in human gliomas. , 1988, British journal of neurosurgery.

[30]  M. Mintun,et al.  Breast cancer: PET imaging of estrogen receptors. , 1988, Radiology.

[31]  L. Old,et al.  Immunogenetics of human cell surface differentiation. , 1989, Annual review of immunology.

[32]  J C Mazziotta,et al.  A Double-Injection Technique for in vivo Measurement of Dopamine D2-Receptor Density in Monkeys with 3-(2'-[18F] Fluoroethyl)Spiperone and Dynamic Positron Emission Tomography , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[33]  L. Farde,et al.  Kinetic Analysis of Central [11C]Raclopride Binding to D2-Dopamine Receptors Studied by PET—A Comparison to the Equilibrium Analysis , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[34]  David J. Schlyer,et al.  Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[35]  R K Jain,et al.  Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. , 1990, Cancer research.

[36]  R. W. Baldwin,et al.  Comparison of biodistribution of 791T/36 monoclonal antibody and its Fab/c fragment in BALB/c mice and nude mice bearing human tumor xenografts. , 1990, Cancer research.

[37]  R. Youle,et al.  Pharmacokinetic analysis of immunotoxin uptake in solid tumors: role of plasma kinetics, capillary permeability, and binding. , 1990, Cancer research.

[38]  J. Bennett,et al.  Apparent synaptic dopamine deficiency induced by withdrawal from chronic cocaine treatment , 1991, Brain Research.

[39]  T. Momose,et al.  Noninvasive method to obtain input function for measuring tissue glucose utilization of thoracic and abdominal organs. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[40]  S. Canevari,et al.  Preclinical pharmacokinetics and localization studies of the radioiodinated anti-ovarian carcinoma MAb MOv18. , 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[41]  E. Hoffman,et al.  Use of the abdominal aorta for arterial input function determination in hepatic and renal PET studies. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  R. Tompkins,et al.  A quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: effects of antibody immunological properties and tumor antigen expression levels. , 1992, Cancer research.

[43]  D. Bigner,et al.  Localization of fluorine-18-labeled Mel-14 monoclonal antibody F(ab')2 fragment in a subcutaneous xenograft model. , 1992, Cancer research.

[44]  T. Yamaguchi,et al.  Biodistribution of monoclonal antibody A7 and its F(ab′)2 fragment in athymic nude mice bearing human pancreatic carcinoma , 1992, Journal of surgical oncology.

[45]  R. Myers,et al.  Quantitation of Carbon‐11‐labeled raclopride in rat striatum using positron emission tomography , 1992, Synapse.

[46]  L. Seymour Passive tumor targeting of soluble macromolecules and drug conjugates. , 1992, Critical reviews in therapeutic drug carrier systems.

[47]  J S Fowler,et al.  Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[48]  R S Frackowiak,et al.  Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status. , 1993, Brain : a journal of neurology.

[49]  P B Hoffer,et al.  Single photon emission tomography measurement of benzodiazepine receptor number and affinity in primate brain: a constant infusion paradigm with [123I]iomazenil. , 1993, European journal of pharmacology.

[50]  F. Buchegger,et al.  Site-specific conjugation of a radioiodinated phenethylamine derivative to a monoclonal antibody results in increased radioactivity localization in tumor. , 1993, Journal of medicinal chemistry.

[51]  S. Yokota,et al.  Biodistribution and in vivo antitumor efficacy of the systemically administered anti-human T-leukemia immunotoxins and potentiation of their efficacy by alpha-interferon. , 1993, Leukemia research.

[52]  Robert B. Innis,et al.  SPECT Quantification of [123I]Iomazenil Binding to Benzodiazepine Receptors in Nonhuman Primates: II. Equilibrium Analysis of Constant Infusion Experiments and Correlation with in vitro Parameters , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[53]  G. Griffiths,et al.  Processing of antibody‐radioisotope conjugates after binding to the surface of tumor cells , 1994, Cancer.

[54]  M. Willingham,et al.  Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. , 1995, Cancer research.

[55]  N. Volkow,et al.  Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[56]  D J Brooks,et al.  Comparison of Methods for Analysis of Clinical [11C]Raclopride Studies , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[57]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[58]  L. Khawli,et al.  Improved tumor localization and radioimaging with chemically modified monoclonal antibodies. , 1996, Cancer biotherapy & radiopharmaceuticals.

[59]  R. McLendon,et al.  Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. , 1997, Cancer research.

[60]  Vincent J. Cunningham,et al.  Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model , 1997, NeuroImage.

[61]  D. Bigner,et al.  Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate. , 1997, Cancer research.

[62]  S S Gambhir,et al.  A new method to estimate parameters of linear compartmental models using artificial neural networks. , 1998, Physics in medicine and biology.

[63]  C Burger,et al.  A JAVA environment for medical image data analysis: initial application for brain PET quantitation. , 1998, Medical informatics = Medecine et informatique.

[64]  Roger N. Gunn,et al.  Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals , 1998, European Journal of Nuclear Medicine.

[65]  Paul Kinahan,et al.  Attenuation correction for a combined 3D PET/CT scanner. , 1998, Medical physics.

[66]  A. Giaccia,et al.  The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. , 1998, Cancer research.

[67]  C Cobelli,et al.  SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies. , 1998, Metabolism: clinical and experimental.

[68]  D. Bigner,et al.  Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody. , 2000, Cancer research.

[69]  A. Wu,et al.  Designer genes: recombinant antibody fragments for biological imaging. , 2000, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[70]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[71]  R. Jain Delivery of molecular and cellular medicine to solid tumors. , 2001, Advanced drug delivery reviews.

[72]  G. Griffiths,et al.  Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[73]  R. B. Campbell,et al.  In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy , 2001, Nature Medicine.

[74]  H. Maeda The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[75]  G. El Fakhri,et al.  Absolute activity quantitation from projections using an analytical approach: comparison with iterative methods in Tc-99m and I-123 brain SPECT , 2001 .

[76]  R F Muzic,et al.  COMKAT: compartment model kinetic analysis tool. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[77]  S. Gambhir Molecular imaging of cancer with positron emission tomography , 2002, Nature Reviews Cancer.

[78]  R. Weissleder Scaling down imaging: molecular mapping of cancer in mice , 2002, Nature Reviews Cancer.

[79]  Adriaan A Lammertsma,et al.  Radioligand studies: imaging and quantitative analysis , 2002, European Neuropsychopharmacology.

[80]  R. Weissleder,et al.  Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging , 2002, European Radiology.

[81]  J. Frangioni In vivo near-infrared fluorescence imaging. , 2003, Current opinion in chemical biology.

[82]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[83]  S. Gambhir,et al.  Molecular imaging in living subjects: seeing fundamental biological processes in a new light. , 2003, Genes & development.

[84]  G. Griffiths,et al.  Improved iodine radiolabels for monoclonal antibody therapy. , 2003, Cancer research.

[85]  Jeih-San Liow,et al.  Linearized Reference Tissue Parametric Imaging Methods: Application to [11C]DASB Positron Emission Tomography Studies of the Serotonin Transporter in Human Brain , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[86]  W. Isaacs,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Pathological and Molecular Aspects of Prostate Cancer Prostate Cancer Ii , 2022 .

[87]  R. Hicks Beyond FDG: novel PET tracers for cancer imaging , 2003, Cancer imaging : the official publication of the International Cancer Imaging Society.

[88]  D. Sears,et al.  Biochemical evidence for structurally distinct H-2Dd antigens differing in serological properties , 2004, Immunogenetics.

[89]  L. Brannon-Peppas,et al.  Nanoparticle and targeted systems for cancer therapy. , 2004, Advanced drug delivery reviews.

[90]  E. Bröcker,et al.  Criteria for selecting monoclonal antibodies with respect to accumulation in melanoma tissue , 2004, Cancer Immunology, Immunotherapy.

[91]  P. Cullis,et al.  Drug Delivery Systems: Entering the Mainstream , 2004, Science.

[92]  S. Nie,et al.  In vivo cancer targeting and imaging with semiconductor quantum dots , 2004, Nature Biotechnology.

[93]  S. Larson,et al.  Development of a method to measure kinetics of radiolabelled monoclonal antibody in human tumour with applications to microdosimetry: positron emission tomography studies of iodine-124 labelled 3F8 monoclonal antibody in glioma , 1993, European Journal of Nuclear Medicine.

[94]  Rakesh K. Jain,et al.  Vascular and interstitial barriers to delivery of therapeutic agents in tumors , 1990, Cancer and Metastasis Reviews.

[95]  C. Wiele,et al.  Receptor Imaging in Oncology by Means of Nuclear Medicine: Current Status , 2004 .

[96]  Vasilis Ntziachristos,et al.  Looking and listening to light: the evolution of whole-body photonic imaging , 2005, Nature Biotechnology.

[97]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[98]  M. Schwaiger,et al.  Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[99]  Ludwig G Strauss,et al.  Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[100]  Uwe Haberkorn,et al.  Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using68Ga-DOTATOC PET and comparison with18F-FDG PET , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[101]  Anna M Wu,et al.  Arming antibodies: prospects and challenges for immunoconjugates , 2005, Nature Biotechnology.

[102]  Eva M. Sevick-Muraca,et al.  Quantifying molecular specificity of αvβ3 integrin-targeted optical contrast agents with dynamic optical imaging , 2005 .

[103]  Ludwig G. Strauss,et al.  Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients , 1996, European Journal of Nuclear Medicine.

[104]  L. Strauss,et al.  Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[105]  Uwe Haberkorn,et al.  Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[106]  David J. Yang,et al.  Targeted Molecular Imaging in Oncology , 2001, British Journal of Cancer.

[107]  S. Gambhir,et al.  Quantitative PET Imaging of Tumor Integrin αvβ3 Expression with 18F-FRGD2 , 2006 .

[108]  R. Weissleder Molecular Imaging in Cancer , 2006, Science.

[109]  Patrick J. Curran,et al.  Method for quantitative protein-ligand affinity measurements in compound mixtures. , 2007, Analytical chemistry.

[110]  H. Hollema,et al.  In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft , 2007, Journal of Nuclear Medicine.

[111]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[112]  Markus Schwaiger,et al.  [18F]Galacto-RGD Positron Emission Tomography for Imaging of αvβ3 Expression on the Neovasculature in Patients with Squamous Cell Carcinoma of the Head and Neck , 2007, Clinical Cancer Research.

[113]  Wolfgang A. Weber,et al.  Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging , 2007, Proceedings of the National Academy of Sciences.

[114]  Wei Chen,et al.  18F-FDOPA Kinetics in Brain Tumors , 2007, Journal of Nuclear Medicine.

[115]  R. Coleman,et al.  Recommendations on the Use of 18F-FDG PET in Oncology , 2008, Journal of Nuclear Medicine.

[116]  A. van Waarde,et al.  Growth factor/peptide receptor imaging for the development of targeted therapy in oncology. , 2008, Current pharmaceutical design.

[117]  Michael M. Schmidt,et al.  Factors determining antibody distribution in tumors. , 2008, Trends in pharmacological sciences.

[118]  Stephen B. Tuttle,et al.  Magnetic resonance-coupled fluorescence tomography scanner for molecular imaging of tissue. , 2008, The Review of scientific instruments.

[119]  Bart Cornelissen,et al.  Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[120]  R. Weissleder,et al.  Imaging in the era of molecular oncology , 2008, Nature.

[121]  S. Gambhir,et al.  Noninvasive Raman spectroscopy in living mice for evaluation of tumor targeting with carbon nanotubes. , 2008, Nano letters.

[122]  Juan Rosai,et al.  Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: A synopsis of the National Cancer Institute Thyroid Fine‐Needle Aspiration State of the Science Conference , 2008, Diagnostic cytopathology.

[123]  Vladimir Tolmachev,et al.  Disruption of HER2 signalling by the monoclonal antibody trastuzumab or the tyrosine kinase inhibitor lapatinib improves survival of patients with metastatic breast , 2010 .

[124]  Sanjiv S. Gambhir,et al.  Multiplexed imaging of surface enhanced Raman scattering nanotags in living mice using noninvasive Raman spectroscopy , 2009, Proceedings of the National Academy of Sciences.

[125]  Christopher H Contag,et al.  Quantifying cell-surface biomarker expression in thick tissues with ratiometric three-dimensional microscopy. , 2009, Biophysical journal.

[126]  Sung-Cheng Huang,et al.  Derivation of a Compartmental Model for Quantifying 64Cu-DOTA-RGD Kinetics in Tumor-Bearing Mice , 2009, Journal of Nuclear Medicine.

[127]  H. Wester,et al.  Molecular imaging targeting peptide receptors. , 2009, Methods.

[128]  Vasilis Ntziachristos,et al.  In vivo investigation of breast cancer progression by use of an internal control. , 2009, Neoplasia.

[129]  Jonathan T. C. Liu,et al.  Ratiometric 3-D Scanning Cytometer for Quantifying Cell-Surface Biomarker Expression within Intact Tissues , 2009 .

[130]  Tayyaba Hasan,et al.  Imaging targeted-agent binding in vivo with two probes. , 2010, Journal of biomedical optics.

[131]  V. Chernomordik,et al.  Quantitative Analysis of HER2 Receptor Expression In Vivo by Near-Infrared Optical Imaging , 2010 .

[132]  J. Frangioni,et al.  Image-Guided Surgery Using Invisible Near-Infrared Light: Fundamentals of Clinical Translation , 2010, Molecular imaging.

[133]  Hak Soo Choi,et al.  Nanoparticles for Biomedical Imaging: Fundamentals of Clinical Translation , 2010, Molecular imaging.

[134]  Ralph Weissleder,et al.  Near-infrared fluorescence: application to in vivo molecular imaging. , 2010, Current opinion in chemical biology.

[135]  T. Gruenberger,et al.  Evaluation of Chemotherapy-Associated Liver Injury in Patients with Colorectal Cancer Liver Metastases Using Indocyanine Green Clearance Testing , 2011, Annals of Surgical Oncology.

[136]  S. Stone-Elander,et al.  Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. , 2010, The Lancet. Oncology.

[137]  V. Chernomordik,et al.  Quantitative analysis of Her2 receptor expression in vivo by near-infrared optical imaging. , 2009, Molecular imaging.

[138]  Ralph Weissleder,et al.  Quantitating Antibody Uptake In Vivo: Conditional Dependence on Antigen Expression Levels , 2011, Molecular Imaging and Biology.

[139]  Scott C Davis,et al.  Pre-clinical whole-body fluorescence imaging: Review of instruments, methods and applications. , 2010, Journal of photochemistry and photobiology. B, Biology.

[140]  J. Humm,et al.  Pharmacokinetic Assessment of the Uptake of 16β-18F-Fluoro-5α-Dihydrotestosterone (FDHT) in Prostate Tumors as Measured by PET , 2010, Journal of Nuclear Medicine.

[141]  Seulki Lee,et al.  Peptides and peptide hormones for molecular imaging and disease diagnosis. , 2010, Chemical reviews.

[142]  Hisataka Kobayashi,et al.  Target-cancer-cell-specific activatable fluorescence imaging probes: rational design and in vivo applications. , 2011, Accounts of chemical research.

[143]  Erlong Zhang,et al.  A review of NIR dyes in cancer targeting and imaging. , 2011, Biomaterials.

[144]  Ralph Weissleder,et al.  A Systems Approach for Tumor Pharmacokinetics , 2011, PloS one.

[145]  Jason R. Gunn,et al.  In Vivo Quantification of Tumor Receptor Binding Potential with Dual-Reporter Molecular Imaging , 2012, Molecular Imaging and Biology.

[146]  W. Oyen,et al.  Immuno-PET of Cancer: A Revival of Antibody Imaging , 2011, The Journal of Nuclear Medicine.

[147]  Jason S. Lewis,et al.  Magnitude of Enhanced Permeability and Retention Effect in Tumors with Different Phenotypes: 89Zr-Albumin as a Model System , 2011, The Journal of Nuclear Medicine.

[148]  Irène Buvat,et al.  Review and current status of SPECT scatter correction , 2011, Physics in medicine and biology.

[149]  Federico Turkheimer,et al.  Quantification of receptor-ligand binding with [18F]fluciclatide in metastatic breast cancer patients , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[150]  Jun Fang,et al.  The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. , 2011, Advanced drug delivery reviews.

[151]  P. Low,et al.  Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results , 2011, Nature Medicine.

[152]  Kirsten Schmieder,et al.  Pharmacokinetic Studies of 68Ga-Labeled Bombesin (68Ga-BZH3) and F-18 FDG PET in Patients With Recurrent Gliomas and Comparison to Grading: Preliminary Results , 2011, Clinical nuclear medicine.

[153]  Brian W. Pogue,et al.  High Vascular Delivery of EGF, but Low Receptor Binding Rate Is Observed in AsPC-1 Tumors as Compared to Normal Pancreas , 2011, Molecular Imaging and Biology.

[154]  L. Strauss,et al.  Correlation of the Ga-68-Bombesin Analog Ga-68-BZH3 with Receptors Expression in Gliomas as Measured by Quantitative Dynamic Positron Emission Tomography (dPET) and Gene Arrays , 2011, Molecular Imaging and Biology.

[155]  Federico Turkheimer,et al.  Importance of Quantification for the Analysis of PET Data in Oncology: Review of Current Methods and Trends for the Future , 2012, Molecular Imaging and Biology.

[156]  P. Choyke,et al.  Near infrared fluorescence‐guided real‐time endoscopic detection of peritoneal ovarian cancer nodules using intravenously injected indocyanine green , 2011, International journal of cancer.

[157]  Eliot T. McKinley,et al.  Quantitative, Preclinical PET of Translocator Protein Expression in Glioma Using 18F-N-Fluoroacetyl-N-(2,5-Dimethoxybenzyl)-2-Phenoxyaniline , 2011, The Journal of Nuclear Medicine.

[158]  Mark Lubberink,et al.  Development of [11C]erlotinib Positron Emission Tomography for In Vivo Evaluation of EGF Receptor Mutational Status , 2012, Clinical Cancer Research.

[159]  C. Brennan,et al.  A Brain Tumor Molecular Imaging Strategy Using A New Triple-Modality MRI-Photoacoustic-Raman Nanoparticle , 2011, Nature Medicine.

[160]  Quanzheng Li,et al.  Dynamic PET and Optical Imaging and Compartment Modeling using a Dual-labeled Cyclic RGD Peptide Probe , 2012, Theranostics.

[161]  V. Chernomordik,et al.  In Vivo Method to Monitor Changes in HER2 Expression Using Near-Infrared Fluorescence Imaging , 2012, Molecular imaging.

[162]  D. Bornhop,et al.  Recent advances in receptor-targeted fluorescent probes for in vivo cancer imaging. , 2012, Current medicinal chemistry.

[163]  Keith St. Lawrence,et al.  Arterial input function of an optical tracer for dynamic contrast enhanced imaging can be determined from pulse oximetry oxygen saturation measurements. , 2012, Physics in medicine and biology.

[164]  Jean-Philippe Pignol,et al.  Role of antibody-mediated tumor targeting and route of administration in nanoparticle tumor accumulation in vivo. , 2012, Molecular pharmaceutics.

[165]  Christopher H Contag,et al.  Microscopic Delineation of Medulloblastoma Margins in a Transgenic Mouse Model Using a Topically Applied VEGFR-1 Probe. , 2012, Translational oncology.

[166]  Sanjiv S Gambhir,et al.  A molecular imaging primer: modalities, imaging agents, and applications. , 2012, Physiological reviews.

[167]  Lixin Lang,et al.  Quantitative Analysis and Comparison Study of [18F]AlF-NOTA-PRGD2, [18F]FPPRGD2 and [68Ga]Ga-NOTA-PRGD2 Using a Reference Tissue Model , 2012, PloS one.

[168]  E M Sevick-Muraca,et al.  Translation of near-infrared fluorescence imaging technologies: emerging clinical applications. , 2012, Annual review of medicine.

[169]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[170]  T. Hasan,et al.  Advantages of a dual-tracer model over reference tissue models for binding potential measurement in tumors , 2012, Physics in medicine and biology.

[171]  Keith D. Paulsen,et al.  Quantitative, spectrally-resolved intraoperative fluorescence imaging , 2012, Scientific Reports.

[172]  Alexander L Vahrmeijer,et al.  Dual wavelength tumor targeting for detection of hypopharyngeal cancer using near‐infrared optical imaging in an animal model , 2012, International journal of cancer.

[173]  V. Chernomordik,et al.  Affibody-DyLight Conjugates for In Vivo Assessment of HER2 Expression by Near-Infrared Optical Imaging , 2012, PloS one.

[174]  S. Batra,et al.  Recent trends in antibody-based oncologic imaging. , 2012, Cancer letters.

[175]  K Dane Wittrup,et al.  Practical theoretic guidance for the design of tumor-targeting agents. , 2012, Methods in enzymology.

[176]  Rakesh K Jain,et al.  Delivery of molecular and cellular medicine to solid tumors. , 1997, Advanced drug delivery reviews.

[177]  J. Wolchok,et al.  Antibody therapy of cancer , 2012, Nature Reviews Cancer.

[178]  D. Longo,et al.  Tumor heterogeneity and personalized medicine. , 2012, The New England journal of medicine.

[179]  Tayyaba Hasan,et al.  Improved tumor contrast achieved by single time point dual-reporter fluorescence imaging. , 2012, Journal of biomedical optics.

[180]  Jason R. Gunn,et al.  Tumor Endothelial Marker Imaging in Melanomas Using Dual-Tracer Fluorescence Molecular Imaging , 2014, Molecular Imaging and Biology.

[181]  Scott C Davis,et al.  Dual-tracer background subtraction approach for fluorescent molecular tomography , 2013, Journal of biomedical optics.

[182]  Christopher H Contag,et al.  A Raman-based endoscopic strategy for multiplexed molecular imaging , 2013, Proceedings of the National Academy of Sciences.

[183]  Kristian J. Sexton,et al.  Direct Characterization of Arterial Input Functions by Fluorescence Imaging of Exposed Carotid Artery to Facilitate Kinetic Analysis , 2014, Molecular Imaging and Biology.

[184]  T. Franosch,et al.  Anomalous transport in the crowded world of biological cells , 2013, Reports on progress in physics. Physical Society.

[185]  R. Jain Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[186]  S. Jacques Optical properties of biological tissues: a review , 2013, Physics in medicine and biology.

[187]  A. Vahrmeijer,et al.  Image-guided cancer surgery using near-infrared fluorescence , 2013, Nature Reviews Clinical Oncology.

[188]  Sophie J Deharvengt,et al.  Dynamic dual-tracer MRI-guided fluorescence tomography to quantify receptor density in vivo , 2013, Proceedings of the National Academy of Sciences.

[189]  R. Jain,et al.  Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. , 2013, Cancer research.

[190]  S. Larson,et al.  Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[191]  Thomas D. Wang,et al.  Advancing the translation of optical imaging agents for clinical imaging , 2012, Biomedical optics express.

[192]  J. Bading,et al.  Functional Imaging of Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Using 64Cu-DOTA-Trastuzumab PET , 2014, The Journal of Nuclear Medicine.

[193]  N. Sanai,et al.  Trends in fluorescence image-guided surgery for gliomas. , 2014, Neurosurgery.

[194]  Tayyaba Hasan,et al.  Comparison of Kinetic Models for Dual-Tracer Receptor Concentration Imaging in Tumors. , 2014, Austin journal of biomedical engineering.

[195]  Sung-Cheng Huang,et al.  Improved Modeling of In Vivo Kinetics of Slowly Diffusing Radiotracers for Tumor Imaging , 2014, The Journal of Nuclear Medicine.

[196]  Jonathan T. C. Liu,et al.  Modulated Alignment Dual-Axis (MAD) Confocal Microscopy for Deep Optical Sectioining in Tissues , 2014, 2014 International Symposium on Optomechatronic Technologies.

[197]  V. Chernomordik,et al.  In Vivo Assessment of HER2 Receptor Density in HER2-positive Tumors by Near-infrared Imaging, Using Repeated Injections of the Fluorescent Probe , 2014, Technology in cancer research & treatment.

[198]  Tayyaba Hasan,et al.  Microscopic lymph node tumor burden quantified by macroscopic dual-tracer molecular imaging , 2014, Nature Medicine.

[199]  B. Wood,et al.  A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies. , 2014, Cancer research.

[200]  E. D. de Vries,et al.  ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody 89Zr-RG7116 , 2014, mAbs.

[201]  B. Pogue,et al.  Pixel-based absorption correction for dual-tracer fluorescence imaging of receptor binding potential. , 2014, Biomedical optics express.

[202]  Brian C Wilson,et al.  Rapid ratiometric biomarker detection with topically applied SERS nanoparticles. , 2014, Technology.

[203]  T. Hasan,et al.  Accounting for pharmacokinetic differences in dual-tracer receptor density imaging , 2014, Physics in medicine and biology.

[204]  Ø. Bruland,et al.  Advantage of lutetium-177 versus radioiodine immunoconjugate in targeted radionuclide therapy of b-cell tumors. , 2014, Anticancer research.

[205]  Daphne Meza,et al.  Comprehensive spectral endoscopy of topically applied SERS nanoparticles in the rat esophagus. , 2014, Biomedical optics express.

[206]  Tayyaba Hasan,et al.  Quantitative in vivo immunohistochemistry of epidermal growth factor receptor using a receptor concentration imaging approach. , 2014, Cancer research.

[207]  H. Lyerly,et al.  Improved Tumor Targeting of Anti-HER2 Nanobody Through N-Succinimidyl 4-Guanidinomethyl-3-Iodobenzoate Radiolabeling , 2014, The Journal of Nuclear Medicine.

[208]  Jovan G. Brankov,et al.  Quantification of the binding potential of cell-surface receptors in fresh excised specimens via dual-probe modeling of SERS nanoparticles , 2015, Scientific Reports.

[209]  Mark Slifstein,et al.  Quantitative imaging of protein targets in the human brain with PET , 2015, Physics in medicine and biology.